Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Evolution of coreceptor utilization to escape CCR5 antagonist therapy.

Zhang J, Gao X, Martin J, Rosa B, Chen Z, Mitreva M, Henrich T, Kuritzkes D, Ratner L.

Virology. 2016 Jul;494:198-214. doi: 10.1016/j.virol.2016.04.010. Epub 2016 Apr 26.

2.

Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.

Curreli F, Kwon YD, Zhang H, Scacalossi D, Belov DS, Tikhonov AA, Andreev IA, Altieri A, Kurkin AV, Kwong PD, Debnath AK.

J Med Chem. 2015 Sep 10;58(17):6909-27. doi: 10.1021/acs.jmedchem.5b00709. Epub 2015 Aug 28.

3.

Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs.

Murray MK, Teran VA, Chapleau JP, Wang B, Kim SH, LaBranche CC, Richard J, Montefiori DC, Finzi A, Yuan W.

J Virol. 2015 Oct;89(20):10707-11. doi: 10.1128/JVI.01642-15. Epub 2015 Aug 5.

4.

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Wolstein O, Boyd M, Millington M, Impey H, Boyer J, Howe A, Delebecque F, Cornetta K, Rothe M, Baum C, Nicolson T, Koldej R, Zhang J, Keech N, Camba Colón J, Breton L, Bartlett J, An DS, Chen IS, Burke B, Symonds GP.

Mol Ther Methods Clin Dev. 2014 Feb 12;1:11. doi: 10.1038/mtm.2013.11. eCollection 2014.

5.

Determination of HIV-1 coreceptor tropism using proviral DNA in women before and after viral suppression.

Baumann RE, Rogers AA, Hamdan HB, Burger H, Weiser B, Gao W, Anastos K, Young M, Meyer WA 3rd, Pesano RL, Kagan RM.

AIDS Res Ther. 2015 Apr 18;12:11. doi: 10.1186/s12981-015-0055-x. eCollection 2015.

6.

CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.

Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P.

PLoS One. 2014 Dec 26;9(12):e115987. doi: 10.1371/journal.pone.0115987. eCollection 2014.

7.

Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection.

de Carvalho JV, de Castro RO, da Silva EZ, Silveira PP, da Silva-Januário ME, Arruda E, Jamur MC, Oliver C, Aguiar RS, daSilva LL.

PLoS One. 2014 Nov 25;9(11):e113691. doi: 10.1371/journal.pone.0113691. eCollection 2014.

8.

A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects.

Brown J, Burger H, Weiser B, Pollard RB, Li XD, Clancy LJ, Baumann RE, Rogers AA, Hamdan HB, Pesano RL, Kagan RM.

AIDS Res Ther. 2014 May 21;11:14. doi: 10.1186/1742-6405-11-14. eCollection 2014.

9.

Mechanisms underlying HIV-1 Vpu-mediated viral egress.

Roy N, Pacini G, Berlioz-Torrent C, Janvier K.

Front Microbiol. 2014 May 1;5:177. doi: 10.3389/fmicb.2014.00177. eCollection 2014. Review.

10.

Antibody epitopes on g protein-coupled receptors mapped with genetically encoded photoactivatable cross-linkers.

Ray-Saha S, Huber T, Sakmar TP.

Biochemistry. 2014 Mar 4;53(8):1302-10. doi: 10.1021/bi401289p. Epub 2014 Feb 18.

11.

Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.

Kagan RM, Johnson EP, Siaw MF, Van Baelen B, Ogden R, Platt JL, Pesano RL, Lefebvre E.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):151-9. doi: 10.1089/AID.2013.0123. Epub 2013 Aug 14.

12.

HIV takes double hit before entry.

Sanders RW.

BMC Biol. 2013 Dec 7;10:99. doi: 10.1186/1741-7007-10-99.

13.

A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.

Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL.

PLoS One. 2012;7(9):e46334. doi: 10.1371/journal.pone.0046334. Epub 2012 Sep 27.

14.

Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu.

Magadán JG, Bonifacino JS.

J Virol. 2012 Jan;86(2):757-72. doi: 10.1128/JVI.05933-11. Epub 2011 Nov 16.

15.

Molecular aspects of HTLV-1 entry: functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors.

Jones KS, Lambert S, Bouttier M, Bénit L, Ruscetti FW, Hermine O, Pique C.

Viruses. 2011 Jun;3(6):794-810. doi: 10.3390/v3060794. Epub 2011 Jun 15. Review.

16.

Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.

Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, Princiotto A, McGee K, Pacheco B, Seaman MS, Smith AB 3rd, Sodroski J.

PLoS Pathog. 2011 Jun;7(6):e1002101. doi: 10.1371/journal.ppat.1002101. Epub 2011 Jun 23.

17.

Modulation of HIV-1-host interaction: role of the Vpu accessory protein.

Dubé M, Bego MG, Paquay C, Cohen ÉA.

Retrovirology. 2010 Dec 22;7:114. doi: 10.1186/1742-4690-7-114. Review.

18.

All-atom models of the membrane-spanning domain of HIV-1 gp41 from metadynamics.

Gangupomu VK, Abrams CF.

Biophys J. 2010 Nov 17;99(10):3438-44. doi: 10.1016/j.bpj.2010.09.054.

19.

Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Tarnowski M, Grymula K, Liu R, Tarnowska J, Drukala J, Ratajczak J, Mitchell RA, Ratajczak MZ, Kucia M.

Mol Cancer Res. 2010 Oct;8(10):1328-43. doi: 10.1158/1541-7786.MCR-10-0288. Epub 2010 Sep 22.

20.

Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Shi B, Kitchen C, Weiser B, Mayers D, Foley B, Kemal K, Anastos K, Suchard M, Parker M, Brunner C, Burger H.

Virology. 2010 Aug 15;404(1):5-20. doi: 10.1016/j.virol.2010.04.008. Epub 2010 May 8.

Supplemental Content

Support Center